Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.45 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371634 | 0.86 | FURIN (0.51) | FURINHRH1GHSRCDYL2CDYL | |
| SCHEMBL20964436 | 0.83 | PRSS1 (0.61) | FURINGHSRPRSS1PRSS2PRSS3 | |
| SCHEMBL1371635 | 0.83 | MMP2 (0.55) | MMP2OPRK1 | |
| SCHEMBL22268858 | 0.82 | OPRK1 (0.52) | FURINGHSRMMP2OPRK1GNPAT | |
| SCHEMBL30818411 | 0.80 | FURIN (0.57) | FURINHRH1GHSRMMP2CDYL2 | |
| SCHEMBL29868240 | 0.79 | OPRK1 (0.58) | MMP2OPRK1GNPAT | |
| SCHEMBL30977978 | 0.78 | OPRK1 (0.55) | MMP2OPRK1GNPAT | |
| SCHEMBL30099540 | 0.78 | MMP2 (0.56) | FURINGHSRMMP2OPRK1CTSL | |
| SCHEMBL22133739 | 0.77 | GNPAT (0.52) | FURINGHSRMMP2OPRK1GNPAT | |
| SCHEMBL17725968 | 0.77 | GHSR (0.68) | GHSRCTSLGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FURIN 45/4885HRH1 2977/4885GHSR 1146/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FURIN 45/4885HRH1 2977/4885GHSR 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.